Norspan Efficacy and Safety Among Elderly Subjects
Primary Purpose
Osteoarthritis Pain of the Hip and or Knee
Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
Buprenorphine transdermal patch
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis Pain of the Hip and or Knee
Eligibility Criteria
Summary Criteria for Inclusion:
- Males and females aged 50-60 or ≥ 75 years.
- Subjects with clinical diagnosis of osteoarthritis in knee and/or hip including fulfilment of ACR-criteria and radiographic evidence not older than one year.
- Subjects with a moderate to severe pain, confirmed by a BS-11 score ≥ 4 for their pain on average during the last seven days of the Screening Phase in their primary OA-site at the Baseline Visit.
Summary Criteria for Exclusion:
- Subjects recording < 4 on average during the Screening Phase on the BS-11 scale.
- Subjects treated with high-potent opioid analgesics (e.g. morphine, fentanyl, oxycodone, methadone, hydromorphone, ketobemidone, buprenorphine) for their osteoarthritis pain.
- Subjects treated with a regular dose for > 1 week of tramadol, codeine or dextropropoxyphene within 1 month before screening visit.
- Subjects who require NSAID treatment (except aspirin for cardiovascular indications) or cox-2-inhibitors during the study period.
- Subjects with history of, or ongoing, chronic condition(s), in addition to osteoarthritis, requiring frequent analgesic therapy (e.g. frequent headaches, frequent migraine, gout, rheumatoid arthritis).
- Subjects scheduled for surgery that would fall within the study period.
- Subjects who currently abused substance or alcohol, or subjects who, in the opinion of the Investigator, have demonstrated addictive or substance abuse behaviours.
- Subjects with cancer (except basal cell carcinoma) or history of cancer in the last 5 years (except treated basal cell carcinoma).
- Untreated depression or other psychiatric disorder in such way that participation in the study may, in the opinion of the Investigator, pose an unacceptable risk to the subject.
- Subjects who are currently taking hypnotics, anxiolytics or other central nervous system depressants that, in the Investigator's opinion, may pose a risk of additional CNS depression with study medication.
- Subjects who are currently taking adjuvant analgesics such as antidepressants and anti-convulsants.
- Dermatological disorder or non-intact skin at any relevant patch application site that precludes proper placement and/or rotation of patch placement.
- Subjects who had received an intra-articular steroid injection within 6 weeks prior Screening Visit or subjects who require steroid treatment (oral, intra-muscular, intra-venous, intra-articular, epidural or other corticosteroid injections) during the study period.
- Subjects with joint evacuation 6 weeks prior Screening Visit and during the study.
- Subjects who are currently taking monoamine oxidase inhibitors (MAOI's) or have taken MAOI's within 2 weeks before Screening Visit.
Sites / Locations
- Professor Jon Karlsson
- Dr Bengt Olav Tengmark
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Buprenorphine transdermal patch
Arm Description
For two age groups: 50-60 years and >= 75 years of age
Outcomes
Primary Outcome Measures
Box Scale-11 (BS-11) pain scores (pain on average during the last seven days, mean change from Baseline to Completion (fulfilled all visits in the study).
Secondary Outcome Measures
Western Ontario & McMaster Universities OA Index
European QOL Health Questionnaire
Sleep disturbance & quality of sleep questions
Patients global assessment of pain relief
Investigators global assessment of pain relief
Incidence of rescue medication
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01276431
Brief Title
Norspan Efficacy and Safety Among Elderly Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
March 2011 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
August 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mundipharma AB
4. Oversight
5. Study Description
Brief Summary
An open label, multi-centre, prospective age-group-controlled study to evaluate efficacy and safety of buprenorphine transdermal patches in subjects with chronic, moderate to severe osteoarthritis pain of the hip and/or knee.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis Pain of the Hip and or Knee
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
102 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Buprenorphine transdermal patch
Arm Type
Other
Arm Description
For two age groups: 50-60 years and >= 75 years of age
Intervention Type
Drug
Intervention Name(s)
Buprenorphine transdermal patch
Primary Outcome Measure Information:
Title
Box Scale-11 (BS-11) pain scores (pain on average during the last seven days, mean change from Baseline to Completion (fulfilled all visits in the study).
Secondary Outcome Measure Information:
Title
Western Ontario & McMaster Universities OA Index
Title
European QOL Health Questionnaire
Title
Sleep disturbance & quality of sleep questions
Title
Patients global assessment of pain relief
Title
Investigators global assessment of pain relief
Title
Incidence of rescue medication
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Summary Criteria for Inclusion:
Males and females aged 50-60 or ≥ 75 years.
Subjects with clinical diagnosis of osteoarthritis in knee and/or hip including fulfilment of ACR-criteria and radiographic evidence not older than one year.
Subjects with a moderate to severe pain, confirmed by a BS-11 score ≥ 4 for their pain on average during the last seven days of the Screening Phase in their primary OA-site at the Baseline Visit.
Summary Criteria for Exclusion:
Subjects recording < 4 on average during the Screening Phase on the BS-11 scale.
Subjects treated with high-potent opioid analgesics (e.g. morphine, fentanyl, oxycodone, methadone, hydromorphone, ketobemidone, buprenorphine) for their osteoarthritis pain.
Subjects treated with a regular dose for > 1 week of tramadol, codeine or dextropropoxyphene within 1 month before screening visit.
Subjects who require NSAID treatment (except aspirin for cardiovascular indications) or cox-2-inhibitors during the study period.
Subjects with history of, or ongoing, chronic condition(s), in addition to osteoarthritis, requiring frequent analgesic therapy (e.g. frequent headaches, frequent migraine, gout, rheumatoid arthritis).
Subjects scheduled for surgery that would fall within the study period.
Subjects who currently abused substance or alcohol, or subjects who, in the opinion of the Investigator, have demonstrated addictive or substance abuse behaviours.
Subjects with cancer (except basal cell carcinoma) or history of cancer in the last 5 years (except treated basal cell carcinoma).
Untreated depression or other psychiatric disorder in such way that participation in the study may, in the opinion of the Investigator, pose an unacceptable risk to the subject.
Subjects who are currently taking hypnotics, anxiolytics or other central nervous system depressants that, in the Investigator's opinion, may pose a risk of additional CNS depression with study medication.
Subjects who are currently taking adjuvant analgesics such as antidepressants and anti-convulsants.
Dermatological disorder or non-intact skin at any relevant patch application site that precludes proper placement and/or rotation of patch placement.
Subjects who had received an intra-articular steroid injection within 6 weeks prior Screening Visit or subjects who require steroid treatment (oral, intra-muscular, intra-venous, intra-articular, epidural or other corticosteroid injections) during the study period.
Subjects with joint evacuation 6 weeks prior Screening Visit and during the study.
Subjects who are currently taking monoamine oxidase inhibitors (MAOI's) or have taken MAOI's within 2 weeks before Screening Visit.
Facility Information:
Facility Name
Professor Jon Karlsson
City
Molndal
Country
Sweden
Facility Name
Dr Bengt Olav Tengmark
City
Stockholm
Country
Sweden
12. IPD Sharing Statement
Citations:
PubMed Identifier
24320787
Citation
Karlsson J, Soderstrom A, Augustini BG, Berggren AC. Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. Curr Med Res Opin. 2014 Apr;30(4):575-87. doi: 10.1185/03007995.2013.873714. Epub 2013 Dec 23.
Results Reference
background
Links:
URL
http://www.informahealthcare.com/doi/abs/10.1185/03007995.2013.873714
Description
Inform Healthcare. Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients. Click here for more information about this study.
Learn more about this trial
Norspan Efficacy and Safety Among Elderly Subjects
We'll reach out to this number within 24 hrs